Fool.com
The World's Greatest Investing Community
Results 41 - 50 of 297 : Previous 1 2 3 4 5 6 7 8 9 Next
Alnylam Lays Down a Sacrifice Bunt
Will RNAi be playing in October?
… Avandia's not going to make a comeback for GlaxoSmithKline.
Dramas are for soaps.
Pfizer: If You Can't Beat 'Em, Join 'Em
Sutent fails. Again.
Meet the People Who'll Rule Your Investment Life
If you're a drug company investor, that is.
It's Approved! Now Back to Work
Bristol-Myers breathes a sigh of relief.
CAPS players who score 100 points in 100 days have become some of the best investors around.
A triple-triple -- three positive phase 3 trials.
Can the European giant produce enough new drugs to offset a series of upcoming patent expirations?
Clinical Trial Positive, Stock Not So Much
Isis and Genzyme hit a homer, but they'll need another big play to win the game.
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK